Show simple item record

dc.contributor.authorBarnebey, H.S.
dc.contributor.authorRobin, A.L.
dc.date.accessioned2019-09-19T18:35:44Z
dc.date.available2019-09-19T18:35:44Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85010297198&doi=10.1016%2fj.ajo.2016.12.002&partnerID=40&md5=af5d656ea95b173924eec1c8de43056f
dc.identifier.urihttp://hdl.handle.net/10713/10935
dc.description.abstractPurpose: To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids. Design: Randomized, controlled, observer-masked clinical trial. Methods: SETTING: Two US clinical sites. PATIENT POPULATION: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months. INTERVENTION: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids. MAIN OUTCOME MEASURE: Adherence with administered medication, as recorded by the dosing aids. Results: Mean ± SD patient age was 60 ± 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on ?80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group). Conclusions: Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy. Copyright 2016 The Author(s)en_US
dc.description.urihttps://doi.org/10.1016/j.ajo.2016.12.002en_US
dc.language.isoen_USen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofAmerican Journal of Ophthalmology
dc.subject.meshGlaucomaen_US
dc.subject.meshOcular Hypertensionen_US
dc.subject.meshTravoprosten_US
dc.subject.meshTimololen_US
dc.titleAdherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ajo.2016.12.002
dc.identifier.pmid27993589


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record